TriSTAR0704

TriSTAR0704 is an experimental trispecific antibody being developed by Marengo Therapeutics for the treatment of various oncology indications. It is built upon the company's proprietary TriSTAR platform, which is an evolution of their Selective T Cell Activation and Rejuvenation (STAR) technology. The TriSTAR platform is designed to create multi-functional antibodies that can simultaneously engage multiple targets, typically combining T cell activation signals with tumor-specific binding or other immune-modulating components. While the specific molecular targets and exact mechanism of action for TriSTAR0704 have not been publicly disclosed, the program represents a next-generation approach to immunotherapy aimed at enhancing the precision and potency of the anti-tumor immune response. It is currently in the early stages of development within Marengo's oncology pipeline.